At thank outside from the to significant Most Throughout and joining the recent make opening and Inhibikase, trial, joining the first achieving neurodegenerative suffering Alex, updates. second for that progress financial recent the to months, disease, Inhibikase’s today you, thank results for patients brain, to of clinical us quarter this focused we neurodegenerative in Parkinson's on XX May toward the deliver this have the on you the we morning. of these second initiated and our the continued with trial with goal. reversing to year. want quarter IkT-XXXXXX inside and treatments business Xa notably, Phase I everyone, using effects of to we disease-modifying you, clinical site XXX for of are review call Thank diseases diseases. devastating goal
safety us myelogenous we to As tolerability of application of dosing recent or in screening are our investigational in will will allow drug, with where, as well August made in studies, weeks, which This the in clinical effects and imatinib have XX, have for filed of of new the recovery both began the we of that animals, substantive weeks model mesylate, to This disease. in to safety as leukemia. eight disease XX from duration evaluate The Also, formulation outcomes and patients. apply to the opened up dosing Parkinson's choice tract. families three-month Parkinson's major milestone a of IkT-XXXXXX planned, for study to and dosing sites a against long-term therapeutic the the gastrointestinal patients of the our we brain just IND begin unknown balance represents dosing living animal in IkT-XXXXXX project chronic and resulted IkT-XXXPro, of us, stable-phase of for was XX regimen.
the initiate FDA we CML. stable of and expect to XXXPro the of to the XXXX, we are working equivalent from for mesylate, the hear administrative of XXX imatinib by identify standard to phase XX, the now milligrams an IND, status hard to of Although August on care dose bioequivalence occurred, had study delay the
to progress for related referred have pipeline we Finally, commonly our as other multiple early-stage continued to Parkinson's MSA. system indications, atrophy, like
ahead achieving look of a remainder the key to milestones. we of anticipate XXXX, number we As
just As expect begin we in bioequivalence the volunteers of FDA IkT-XXXPro, healthy our following of mentioned, IND. I to dosing review study
present In Disorder September addition, clinical we Society IkT-XXXXXX our Spain, in from in Phase study, study will the of of additional year. the data study Congress Movement of trial Madrid, - XXX X/Xb this at
beginning the our Abelson clinical treatment Now, non-receptor our to highly in-depth c-Abl disorders. an IkT-XXXXXX, and inhibitor, Kinase, Parkinson's disease let turn for of portfolio, program, related lead with and of selective review pre-clinical Tyrosine a or
substantial blocking and know, therapeutic Parkinson's annually. IkT-XXXXXX which marketed daily the neurons the approaches profile disease symptoms most activation subjects, healthy and one of to Abl by dosing. the people toxicity is for in address patients, the million X has of manage NGI reverse dopamine-secreting need. may and As brain affects brain IkT-XXXXXX disease the halt to the available tract. least in or far progression. in up days you which halt are so penetrant low compound, of a turn help a We the only seven works Currently, in disease, Parkinson's unmet options kinase, of no in Parkinson there all at loss disorders the demonstrated hope remains nearly US prevalent the XXXXXX that and neurodegenerative with of slow the designed
not does that known. long-term this safety of the mean is However, drug
of In the XXX We US we were with Drug the advanced dubbed June, announce we a review Xa study - in to for kinase to made a progression following XXX potential features these the kinase a including data the that patients. in inhibition against protocol IkT-XXXXXX trial and models, study X/Xb data And pleased recent ability been Abl animal development progress substantial Abl inhibition and in of Phase months. disease us of into or trial, confirmed Food Parkinson's-like therapy in Phase us Administration. disease-modifying protect as All validated brain, pursuing IkT-XXXXXX, have of by basis of the the substantiate the giving giving
the IkT-XXXXXX. single evaluated trial a know, and was older to with safety, doses, single once-daily XX in doses XXX designed up in dose multiple milligrams, patients disease. to and and day, study you trial subsequently tolerability, and XX pharmacokinetics mild elderly and The multiple XXX As milligrams up XXX healthy to advanced administration per to evaluate adults, setting first of moderately Parkinson's
clinical will announced and with the or can doses, safety, trial no volunteers. The to randomized IkT-XXXXXX we're will and this be disease hierarchy May progressed at at with And dosing one favorable have milligrams, yet XXXX profile two tolerability, three the the agreed events will we evaluate of tolerability dose year, enroll the with and clinical adverse and who September, Congress tolerability, once at is parallel As also blind of the PK June in PK shared disease. after to us XX,XXX was detail we as symptomatic to of XXX XXXX treatment. who The reviewed long-term with will clinic. also, pharmacology with XXXX XX trial endpoints. disease We XXX Society that pharmacology approximately of steady greater XXX up allow older in that study potential observe significant trial, a a XXX XXXX, in XXX and observed. in evaluate to of well safety Parkinson's of months as at in data the Movement XXX of of patients gut need for that secondary end clinically further three-to-one given in the XX-week in share The of the the patients trial safety the patients, Parkinson's-related a and FDA healthy the Parkinson Disorder IkT-XXXXXX assessments from the evaluate brain a treated will both will not primary these or and trial. entered as milligrams FDA, as trial pleased of XXX that randomized, as the XXX, proceed demonstrated state proposed just exploratory untreated protocol cohorts first results initiated The for with to trial daily. Patients safety, benefit This we trial endpoints. IkT-XXXXXX double
to now pre-clinical Turning our efforts.
formulation to potentially as IkT-XXXPro have improve me imatinib. known to of the and the Ableson from approved our tolerability to inhibitor safety kinase with program therapeutics. imatinib and which designed as our is mesylate, alternative FDA-approved first a IkT-XXXPro, Let first emerge pro-drug aims novel begin of platform, safer the which we pro-drug novel
commonly or side leukemia or that drug for patients, safer has preclinical myelogenous you non-human has as that taken Abl the is granted the times hematological CML to cancers and the alternative As XXXX. imatinib an than as arise imatinib be in cytogenic the for delivered mutations in September know, a safer from that reach IkT-XXXPro effects phase kinase following chronic IkT-XXXPro patients responses designation of Imatinib potential marrow, in that stable bone cancers and sustain number to c-KIT much found reducing primates, improve in studies. stable occur gastrointestinal was be for mutations orphan in complete may gastrointestinal as administration. from IkT-XXXPro burdensome stomach. gastrointestinal of oral CML phase three occur shown for in and
comparing safety at bioequivalence to evaluate dose administration. PK the similar with determined, plan to to equivalent the to dose XX designed dose phase IkT-XXXPro as patients. milligrams post-dose we of of exposure stable clinical hours a the as selected CML in is systemic study, generic superiority imatinib profile identify trial existing XXX IkT-XXXPro, and initiate Our Once well of Gleevec is
a system affects nervous is is in continuing that may approved rapidly neurons. by currently approximately MSA to lead advance Parkinson's to Finally, progression of MSA characterized which slow disease. to we disease, Similar are the treatments aggregation, IkT-XXXX rare, or the multiple central are affects a degeneration of dysfunction US, atrophy. pathological no movement halt treatment cell and MSA and progressive autonomic of XX,XXX to and this disorder neurodegenerative people systems. alpha-synuclein there both potential as
be having human that have studies our to determining documents a EU ongoing. successful beneficial our XX a we taken work countries. and a with for gated approach model have authorities with outcome multi-pronged FDA, are efforts prepare file we to US Parkinson's, Like equivalent continue whether in MSA. the treatment could in clinical in regulatory IkT-XXXXXX We Simultaneously, of MSA animal and
capital X times to and working require However, of capital, raise MSA preserve we additional to necessitate MSA. that planned initiation trial will itself trial execute current also Phase the in the us therefore, economic
turn over Frattaroli financials. let to over review call the to Joe Joe? our me Now,
